LA JOLLA, Calif., June 12, 2017 /PRNewswire/ -- DermTech, Inc., the global leader in non-invasive molecular dermatology, announced that the company has become a Participating Provider with CareFirst Blue Cross/Blue Shield and CareFirst BlueChoice (CareFirst) healthcare insurers for the Pigmented Lesion Assay, the company's non-invasive biopsy and gene expression test for the detection of melanoma. The agreement establishes coverage for CareFirst, the largest health care insurer in the Mid-Atlantic region covering 3.4 million members. Coverage is scheduled to become effective for claims for services performed on or after June 1, 2017.
"This is the first contract of the many anticipated for our skin cancer pathology tests executed directly with one of the larger BlueCross Blue Shield providers, and is supported by the ground breaking publication of our clinical utility study, entitled "Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy" in the April 2017 edition of JAMA Dermatology," said Sarah Dion, VP of Sales and Marketing.
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit: www.dermtech.com.
Sarah Dion, MBA
VP, Sales and Marketing
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermtech-announces-first-payor-contract-with-carefirst-300471478.html
SOURCE DermTech, Inc.